Latest Investment News

Sequoia Financial Group has acknowledged that ASIC’s civil penalty proceedings against its subsidiary InterPrac are material and confirmed timely disclosure to the market following formal notification.

Wesfarmers Limited announces a fully franked special dividend of AUD 0.40 per share alongside a $1.10 capital return, both payable on December 4, 2025. Eligible shareholders can participate in the Dividend Investment Plan for the dividend component, marking a significant move in the company’s 2025 capital management strategy.

Wesfarmers has set the allocation price for shares issued under its Dividend Investment Plan for the special dividend at $81.0055, with just over 12% of shareholders opting in. Shares will be allocated on 4 December 2025.

Elanor Investors Group has extended deadlines for a $125 million investment from Rockworth Capital Partners and the acquisition of Firmus, with a key shareholder meeting now scheduled for late January 2026.

Chrysos Corporation reports nearly one million monthly PhotonAssay samples and reiterates strong FY26 revenue guidance, while unveiling next-gen assay technologies and global expansion plans.

Andromeda Metals has initiated early site works at its Great White Project following the lodgement of a $3.79 million rehabilitation bond and environmental compliance payments. This milestone marks a key step toward advancing the project’s development in South Australia.

Rox Resources (ASX – RXL) has delivered a comprehensive update on its Youanmi Gold Project, highlighting a compelling Definitive Feasibility Study and significant funding progress that set the stage for production in 2026.

Skylark Minerals has acquired a high-grade gold portfolio in Côte d'Ivoire, including a flagship project with a 364,600-ounce inferred resource, marking a significant step in its West African growth strategy. The company is fully funded to accelerate exploration in early 2026, targeting resource expansion and new discoveries.

Pro Medicus Ltd has delivered a record-breaking FY2025 with revenue soaring nearly 32% and net profit up 39%, driven by landmark contracts and a robust growth pipeline.

Chimeric Therapeutics has received a $4.5 million R&D tax incentive refund from the Australian Government, underscoring its ongoing investment in innovative cancer cell therapies.

VHM Limited has raised A$10.3 million through a fully-underwritten institutional placement, advancing its Goschen Project development ahead of a Final Investment Decision in early 2026. A Share Purchase Plan will follow, inviting existing shareholders to participate at the same discounted price.

Brightstar Resources outlines a bold growth strategy targeting over 200,000 ounces of annual gold production by 2029, leveraging its Western Australian assets and aggressive drilling programs. The company’s recent feasibility studies and acquisitions position it as a rising gold producer in the region.